CFTR and Fabry disease: Several pharmacochaperones have recently been approved for clinical use; prominent examples include migalastat and lumacaftor, which restore folding of some mutants of lysosomal α-galactosidase in Fabry’s disease [3] and of CFTR-ΔF508, the most frequently mutated variant of the cystic fibrosis transmembrane conductance regulator (CFTR/ABC-C7) [4].